

**SARC Semiannual Meeting Agenda**  
**Friday, May 29, 2015**

<b>8:00</b>	<b>Opening Remarks</b>	
	Denise Reinke	
<b>8:10</b>	<b>Chawla Rosenfeld Developmental Therapeutics Symposium</b>	
	Introduction	Robert Maki
	Metabolic Reprogramming Drives Sarcomagenesis	Kevin Jones
	Cancer Metabolism: Overview	Matt Vander Heiden
	Translating Cancer Metabolism to Clinic	Brian Van Tine
	<i>Discussion/Q&amp;A</i>	Panel
<b>10:00</b>	<b>Genomic Portal</b>	
	Demonstration	Chand Khanna
<b>10:15</b>	<b>Break</b>	
	Break	
<b>10:30</b>	<b>SARC Clinical Trials</b>	
	Clinical Trials Update	<b>Scott Okuno</b>
	<b>SARC016:</b> Phase 2 trial of bevacizumab & everolimus in unresectable or metastatic MPNST	Brigitte Widemann Presented by <b>Lee Helman</b>
	<b>SARC018-SPORE01:</b> Phase 2 trial of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma	Edwin Choy & Shreyaskumar Patel Presented by <b>Scott Okuno</b>
	<b>SARC021:</b> Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic STS	<b>William Tap</b>
	<b>SARC023:</b> Phase 1/2 trial of ganetespib & sirolimus in unresectable or metastatic MPNST	<b>AeRang Kim</b>
	<b>SARC024:</b> Phase 2 trial of regorafenib in refractory lipo, osteo and Ewing/Ewing-like sarcomas	Robert Maki, Christopher Ryan, Richard Riedel, & <b>Steven Attia</b>
	<b>SARC025-SPORE03:</b> Phase 1 trial of niraparib and temozolomide in incurable Ewing sarcoma	<b>Rashmi Chugh &amp; Sandra Strauss</b>
	<b>SARC028:</b> Phase 2 trial of the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced sarcomas	<b>Hussein Tawbi</b>
<b>11:30</b>	<b>SARC Career Development Awards</b>	
	2015 Awards	<b>Richard Gorlick &amp; Lee Helman</b>
<b>11:45</b>	<b>SARC Sarcoma SPORE</b>	
	Update	<b>Raphael Pollock</b>
	<b>Closing Remarks</b>	